Caribou Biosciences Inc - Asset Resilience Ratio
Caribou Biosciences Inc (CRBU) has an Asset Resilience Ratio of 70.69% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Caribou Biosciences Inc's Asset Resilience Ratio has changed over time. Check CRBU PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Caribou Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Caribou Biosciences Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $126.98 Million | 70.69% |
| Total Liquid Assets | $126.98 Million | 70.69% |
Asset Resilience Insights
- Very High Liquidity: Caribou Biosciences Inc maintains exceptional liquid asset reserves at 70.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Caribou Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Caribou Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896 |
Biotechnology | 12.69% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
Annual Asset Resilience Ratio for Caribou Biosciences Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Caribou Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.41% | $126.98 Million | $175.37 Million | +10.73pp |
| 2024-12-31 | 61.68% | $193.24 Million | $313.31 Million | -2.57pp |
| 2023-12-31 | 64.24% | $277.67 Million | $432.21 Million | +13.59pp |
| 2022-12-31 | 50.65% | $189.32 Million | $373.76 Million | +20.04pp |
| 2021-12-31 | 30.61% | $135.41 Million | $442.36 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $36.05 Million | -- |
| 2019-12-31 | 13.56% | $8.40 Million | $61.93 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more